Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.980 USD -0.230 (-2.80%)
Official Closing Price Updated: 4:21 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Aeglea Biothera

< Previous 1 2 3 4 5 6 7 8 Next >
Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting ... 
Tags URGN IBB ARQL
From Benzinga
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results and ... 
Tags Biotech XBI KIDS
From Benzinga
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
IFR Americas ECM Weekly Wrap
US WEEKLY TOTAL $3,418.3m – IPO $927.0m – ABB/BLOCK $630.7m – FOLLOW-ON $1,375.0m – CB $485.0m Monday Dream Industrial REIT (Canada, industrial REIT) – C$125m Block. 12m units (100% sec) at C$10.45... 
Tags companyNews
From Reuters: Company News
62 Biggest Movers From Yesterday
Gainers MacroGenics, Inc. (NASDAQ: MGNX) surged 130.42 percent to close at $25.60 on Wednesday after reporting positive results ... 
Tags CRON APPS Markets
From Benzinga
48 Stocks Moving In Wednesday's Mid-Day Session
Gainers MacroGenics, Inc. (NASDAQ: MGNX) jumped 150.2 percent to $27.80 after reporting positive results from pivotal Phase 3 ... 
Tags CAW Semiconductors TCS
From Benzinga
IFR Americas ECM Pipeline
NEW YORK, Feb 6 (IFR) - PRICED Aeglea BioTherapeutics (US, biotech) – $60m ABB. 3.75m shares (100% prim) at $8.00 concurrent with 3.75m pre-funded warrants at $7.99 versus $9.40 last sale. JPM, EVER.... 
Tags companyNews
From Reuters: Company News
33 Stocks Moving In Wednesday's Pre-Market Session
Gainers MacroGenics, Inc. (NASDAQ: MGNX) rose 112.7 percent to $23.63 in pre-market trading after reporting positive results from ... 
Tags AGLE USNA VNDA
From Benzinga
The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting ... 
Tags AGLE BNGO Earnings
From Benzinga
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
55 Biggest Movers From Monday
Gainers MINDBODY Inc (NASDAQ: MB) shares jumped 64.96 percent to close at $35.83 on Monday after the company agreed to be acquired ... 
Tags Top Gainers ASTC ALPN
From Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers MINDBODY Inc (NASDAQ: MB) gained 66.7 percent to $36.21 after the company agreed to be acquired by Vista Equity for $36.50 ... 
Tags AGLE DBVT NEON
From Benzinga
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
Company to Webcast Fireside Chat on Wednesday, December 12 at 3:40 p.m. ET 
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
Company to Webcast Fireside Chat on Tuesday, November 27 at 2:45 p.m. ET 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts — New Horizons, Emerging Trends, and
From GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
Look Under The Hood: EQWS Has 27% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs
Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the ... 
Tags NVCR ETTX FDA
From Benzinga
Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting ... 
Tags News Benzinga ACRS
From Benzinga
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European ... 
Tags SELB Benzinga News
From Benzinga
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... 
From GlobeNewswire News Releases
55 Biggest Movers From Yesterday
Gainers MannKind Corporation (NASDAQ: MNKD) surged 89.09 percent to close at $2.08 on Tuesday after the developer of inhaled ... 
Tags Yesterday's Gainers NCTY SRRK
From Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.